Quick Answer
Aptevo Therapeutics Inc. reported Total Revenue of $3.11 million for the year ending 2022.
- Aptevo Therapeutics Inc. showed a decrease of -74.7% in Total Revenue from 2021 to 2022.
- This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2024.
- XBRL data for this metric is available from 2017 to 2022 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $3.53 million | Q3 2017: $6.17 million | Q1 2018: $4.07 million | Q2 2018: $6.83 million | Q3 2018: $5.82 million | Q1 2019: $7.02 million | Q2 2019: $7.36 million | Q3 2019: $9.01 million | Q2 2020: $473.0 thousand | Q3 2020: $1.46 million | Q1 2021: $2.42 million | Q2 2021: $3.11 million | Q3 2021: $3.10 million | Q1 2022: $3.11 million.
- Over the full 6 years of available data (2017 to 2022), Aptevo Therapeutics Inc.'s Total Revenue has declined by 78.8%.
- Historical annual values: Fiscal year 2022: $3.11 million | Fiscal year 2021: $12.29 million | Fiscal year 2020: $4.31 million | Fiscal year 2019: $32.42 million | Fiscal year 2018: $23.07 million | Fiscal year 2017: $14.66 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: